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1.1. Need for developing case definitions, and guidelines for data
collection, analysis, and presentation for antenatal bleeding as an
adverse event
Bleeding in the second and third trimesters of pregnancy affects
6% of all pregnancies, and has distinct etiologies from first-trime-
ster bleeding [1]. In the vast majority of cases, antenatal bleeding
is vaginal and obvious; however, rarely, it may be contained within
the uterine cavity, the intraperitoneal space, or the retroperitoneal
space. The etiologies of antenatal bleeding, also referred to as
antepartum hemorrhage, are heterogeneous. In cases of severe
antepartum hemorrhage, complications include preterm delivery,
cesarean delivery, blood transfusion, coagulopathy, hemodynamic
instability, multi-organ failure, salpingectomy/oophorectomy,
peripartum hysterectomy, and in some cases, either perinatal or
maternal death.
The goal of this Working Group was two-fold:
(1) to define sources of pathologic antenatal bleeding in the sec-
ond or third trimester of pregnancy that are directly attributa-
ble to pregnancy and are either common and/or catastrophic;(2) to define each source of antenatal bleeding for the purposes
of future case ascertainment.
The charge to the Brighton Collaboration Working Groups to
define various adverse obstetric and pediatric events includes an
aim to more easily identify immunization-related adverse events.
In the case of antenatal bleeding, our Working Group felt strongly
that there is no biologic plausibility or mechanistic explanation
linking immunizations to antenatal bleeding. Moreover, as immu-
nizations and antenatal bleeding are common occurrences in the
course of any individual pregnancy, it is quite likely that these
events will co-occur without suggesting causation. To date, there
is one case report of antenatal bleeding occurring in a pregnancy
where a tetanus, diphtheria, and acellular pertussis vaccination
was also administered [2]. However, the definition used to identify
the antenatal bleeding event is not clearly presented. Standardized
definitions across trials, surveillance systems, or clinical settings
will facilitate case ascertainment and analysis of potential risk fac-
tors for antenatal bleeding.
In this document, we focus on placenta previa, morbidly adher-
ent placentation, vasa previa, placental abruption, cesarean scar
pregnancy, intra-abdominal pregnancy, and uterine rupture as
important sources of antenatal bleeding. Cesarean scar pregnancy
and intra-abdominal pregnancy are rarely listed as causes of ante-
natal bleeding in the second and third trimester. Nonetheless, we
included these causes as they are more likely to result in late pre-
sentation with a high risk of heavy maternal bleeding in settings in
which ultrasound diagnosis of pregnancy is limited or unavailable.
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preterm. Although preterm labor is pathologic and addressed in
another document [3], bleeding in the context of labor alone is
not. This is not addressed in our document. Non-obstetric genital
tract bleeding may also occur during pregnancy, including neoplas-
tic, infectious, traumatic, or iatrogenic causes. Urinary tract infec-
tions or hemorrhoids may also be misidentified as antenatal
bleeding until additional workup is performed. This document will
focus solely on the pregnancy-attributable etiologies of antenatal
bleeding.
1.2. Methods for the development of the case definition, and guidelines
for data collection, analysis, and presentation for antenatal bleeding as
an adverse event
Following the process described in the overview paper [4] as
well as on the Brighton Collaboration Website http://www.
brightoncollaboration.org/internet/en/index/process.html, the
Brighton Collaboration Antenatal Bleeding Working Group was
formed in 2016 and includes members with a diverse background
in clinical experience, location of practice, and scientific expertise
in sources of antenatal bleeding. The composition of the working
and reference group as well as results of the web-based survey
completed by the reference group with subsequent discussions in
the working group can be viewed at: http://www.brightoncollabo-
ration.org/internet/en/index/working_groups.html.
To guide decision-making for case definitions, a literature
search was performed in PubMed, including the following terms:
pregnancy, antenatal bleeding, antepartum bleeding, antepartum
hemorrhage, placenta previa, vasa previa, abruptio placenta, pla-
centa accreta, morbidly adherent placenta, abdominal pregnancy,
cesarean scar pregnancy, uterine rupture, abdominal pregnancy,
intra-abdominal pregnancy, and vaccination. Major obstetric text-
books and published guidelines from major obstetric societies
throughout the world were also surveyed. This review resulted in
a detailed summary of 33 articles used to establish case definitions
for antenatal bleeding. The search also resulted in the identifica-
tion of 1 reference containing information regarding vaccination
administration and antenatal bleeding (as defined by the listed
PubMed search terms above).
1.3. Description of sources of antenatal bleeding
We first begin with a brief description of each etiology, the
underlying pathophysiology, incidence, and risk factors. For most
conditions, incidence data are derived from settings in which the
condition has been most systematically studied, often North Amer-
ica and Western Europe. Incidence data not derived from these
areas is specified in the following paragraphs.
1.3.1. Placenta previa
Placenta previa occurs when the placenta partially or com-
pletely overlies the internal cervical os. This is in contrast with
low-lying placenta, in which the placenta lies within 2 cm of the
internal cervical os but does not extend across it. The etiology of
placenta previa is unknown. Risk factors include smoking,
advanced maternal age, multiparity, in vitro fertilization, multiple
gestation, Asian race, prior endometrial damage, prior pregnancy
termination or spontaneous abortion, prior cesarean delivery, and
prior placenta previa [1,5,6]. These risk factors suggest that the
pathogenesis may be driven by endometrial damage or suboptimal
endometrial perfusion in other areas of the uterus. The incidence of
placenta previa at term is approximately 1 in 200 pregnancies; the
incidence is higher earlier in gestation, but many placenta previasresolve as the lower uterine segment develops and the placenta
preferentially expands towards more vascularized areas of the
uterus [1,5].
1.3.2. Morbidly adherent placentation
Morbidly adherent placentation occurs when the placenta
implants abnormally into the uterine myometrium, rather than
the normal implantation of the placenta into the uterine decidua
basalis [1,5,7]. Invasive placentation occurs as a result of the
absence of the decidua basalis and incomplete development of or
injury to Nitabuch’s layer [1,5,8]. The incidence of morbidly adher-
ent placentation is 1 in 300 to 1 in 500 pregnancies [5]. The most
significant risk factor is placenta previa in the context of one or
more prior cesarean deliveries, or other uterine surgery. With
one prior cesarean delivery and a placenta previa, the risk is 11%;
with 3 or more cesarean deliveries and a placenta previa, the risk
is greater than 60% [9]. Other common risk factors include
advanced maternal age, advanced parity, cesarean scar pregnancy,
and in vitro fertilization [5,7,10–12].
1.3.3. Placental abruption
Placental abruption occurs when the placenta detaches prema-
turely from its implantation site. Traditionally conceptualized as
primarily an ‘‘acute” event often resulting from physical trauma
to the abdomen, contemporary data suggest that placental abrup-
tion is often chronic [13–17]. Nevertheless, acute placental abrup-
tions still occur. Abruptions may either be revealed, with vaginal
bleeding as an early symptom, or concealed, with blood remaining
trapped within the uterus. Pathophysiologic mechanisms involved
in abruption include uteroplacental underperfusion, ischemia, pla-
cental infarctions, and chronic hypoxia [18–20]. In very rare cir-
cumstances abruption can follow second trimester diagnostic and
therapeutic intrauterine procedures (amniocentesis, CVS, fetal sur-
gery). Abruption affects about 1% of pregnancies, but is associated
with a recurrence risk of about 10–15% for one prior abruption, 20–
30% after two, and 30% after three or more abruptions [21,22].
Other risk factors include first trimester bleeding, hypertension,
thrombophilia, illicit drug use (especially cocaine), smoking,
trauma, in vitro fertilization, and premature rupture of membranes
[23–26]. Pregnancies diagnosed with abruption end 3–4 weeks
earlier than other pregnancies, with well over half delivering pre-
term. This is in contrast to a preterm birth rate of 12% among unaf-
fected pregnancies [26–29].
1.3.4. Vasa previa
Vasa previa occurs when fetal blood vessels course within the
amniotic membranes across the internal cervical os or within
2 cm of the os. Type I vasa previa occurs with a velamentous
umbilical cord insertion into the membranes, consequently allow-
ing for fetal vessels to run free within the membranes between the
umbilical cord and placenta. Type II vasa previa occurs with the
development of a succenturiate placental lobe and main placental
lobe, connected by fetal vessels that freely course within the mem-
branes. Vasa previa is rare, with an incidence of 1 in 2500 deliver-
ies. Risk factors include resolved low-lying placenta, placenta
previa, and multiple gestation [5,30].
1.3.5. Cesarean scar pregnancy
A cesarean scar pregnancy is an ectopic pregnancy implanted in
a previous cesarean (hysterotomy) scar, surrounded by myome-
trium and connective tissue. This occurs due to a small defect in
the cesarean scar, as a result of poor healing and poor vasculariza-
tion of the lower uterine segment with resultant fibrosis [31]. The
pathophysiology of cesarean scar pregnancies is similar to an
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Cesarean scar pregnancies occur in about 1 in 2000 pregnancies
and account for 6% of ectopic pregnancies among women with a
prior cesarean delivery [31]. As the recognition of cesarean scar
pregnancies is relatively recent, risk factors are not yet clear; how-
ever, as with morbidly adherent placentation, the incidence
appears to correlate with the number of prior cesarean deliveries
[32].
1.3.6. Intra-abdominal pregnancy
Intra-abdominal pregnancy is a rare form of an ectopic preg-
nancy, in which a pregnancy implants into the peritoneal cavity
or abdominal organs. Most commonly, this occurs due to tubal
ectopic pregnancy with tubal extrusion or rupture and secondary
implantation; primary implantation into the peritoneal cavity is
also possible. Pregnancies may be asymptomatic, or may present
with life-threatening intra-abdominal hemorrhage. The incidence
is difficult to ascertain, as data are derived from case reports, but
is reported to be 1–2 in 10,000. Risk factors are artificial insemina-
tion, in vitro fertilization, uterine surgeries, and prior tubal or cor-
nual pregnancy [33,34].
1.3.7. Uterine rupture
Uterine rupture is the complete nonsurgical disruption of all
layers of the uterus. Uterine rupture may occur either in an
unscarred uterus or at the site of a prior hysterotomy scar. The inci-
dence of rupture of the unscarred uterus is approximately 1 in
20,000 deliveries in high-resource settings, but can be as high as
1 in 100 deliveries in low-resource settings, where the majority
of this type of rupture occurs [35–37]. Risk factors for uterine rup-
ture in an unscarred uterus include a contracted pelvis, prolonged
dystotic labor, multiparity, morbidly adherent placentation, malp-
resentation, use of strong uterotonic drugs perhaps with cephalo-
pelvic disproportion, operative vaginal deliveries at high station,
and congenital weakness of the myometrium [35]. In high-
resource settings, uterine rupture most commonly occurs in the
context of a prior hysterotomy scar or transfundal surgery [37].
The incidence of this event ranges from approximately 1 in 200
up to 1 in 10, depending on the type of hysterotomy and the use
of labor augmentation [38,39]. Additional risk factors include the
number of prior cesarean deliveries, interdelivery interval less than
18 months, one-layer uterine closure, and open fetal surgery [40–
42].
1.4. Rationale for selected decisions about case definitions for
antenatal bleeding as an adverse event
1.4.1. Formulating case definitions that reflect diagnostic certainty:
weighing specificity versus sensitivity
The number of signs, symptoms, and diagnostic tests that will
be documented for each case may vary considerably. The case def-
inition has been formulated such that the Level 1 definition is
highly specific for the condition. As maximum specificity normally
implies a loss of sensitivity, an additional diagnostic level has been
included in the definition to increase sensitivity while retaining an
acceptable level of specificity. In this way, it is hoped that all pos-
sible cases of antenatal bleeding can be systematically captured.
The grading of definition levels is about diagnostic certainty, not
clinical severity of an event. Thus, a clinically very severe event
may appropriately be classified as Level 2 or 3 rather than Level
1 if it could reasonably be of an alternative etiology – either
another cause of antenatal bleeding, or unrelated to antenatal
bleeding entirely. Detailed information about the severity of the
event should always be recorded, as specified by the data collec-
tion guidelines [43].1.4.2. Rationale for individual criteria or decision made related to the
case definitions
1.4.2.1. Pathology findings. In certain cases, pathologic findings
serve as the gold standard to confirm the presence of a pathologic
entity. This is the case for morbidly adherent placentation, where
the surgical specimen is often the hysterectomy specimen with
placenta in-situ. Pathologic findings for cesarean scar pregnancy
managed by hysterectomy with the gestational sac in-situ is also
the gold standard for diagnosis; however, a hysterectomy is not
always performed, and histologic confirmation may not be possi-
ble. Histological findings identify many but not all cases of placen-
tal abruption. The other etiologies of antenatal bleeding included
within this document do not lend themselves to a histologic
diagnosis.
1.4.2.2. Laboratory findings. No specific laboratory findings were
included in case definitions of antenatal bleeding, as none of these
clinical entities are associated with specific or identifiable labora-
tory parameters. Anemia and coagulopathy associated with signif-
icant antenatal bleeding are to be diagnosed and managed using
usual clinical algorithms.
1.4.2.3. Radiology findings. Ultrasound findings in a pregnancy com-
plicated by antenatal bleeding are highly important in identifying
and differentiating several conditions and thus are included in
many case definitions. MRI findings may be used in some circum-
stances when this modality is available. See below regarding safety
data.
1.4.3. Safety of imaging in pregnancy
Prenatal ultrasound uses sound waves passing through an
acoustic window to visualize deeper tissue and structures, includ-
ing a fetus. Ultrasound is considered safe in pregnancy, and there
have been no reports of adverse fetal or neonatal outcomes from
prenatal ultrasound imaging. Applying the ALARA (As Low As Rea-
sonably Achievable) principle is recommended during diagnostic
imaging procedures [44,45]. Magnetic resonance imaging (MRI)
technology has also been used in pregnancy for several indications
after inconclusive or nondiagnostic prenatal ultrasound. There has
never been any documented fetal or neonatal harm and the proce-
dure is considered safe in pregnancy. While the quality of imaging
may be superior with gadolinium-enhanced imaging, its use is not
currently recommended in pregnancy due to theoretical harms.
Nonetheless, clear harm from gadolinium has not been demon-
strated [45].
1.4.4. Timing of adverse event with relation to timing of immunization
As noted in the preamble of this document, both immunizations
and antenatal bleeding are common events in pregnancy. We feel
strongly there is no current evidence or biological plausibility to
suggest a causal link between immunization and antenatal bleed-
ing. In order to appropriately assess this question, pregnant
women who are and are not exposed to immunizations would
need to be prospectively studied to identify any association with
antenatal bleeding. However, withholding immunizations in preg-
nancy would not be ethical, and thus we are left with case reports
and other epidemiologic studies of association that may lead to
inappropriate conclusions.
1.4.5. Differentiation from other associated disorders
As previously discussed, the focus of this Working Group is to
define pathologic primary causes of antenatal bleeding. Labor,
whether at term or preterm, may present with vaginal bleeding,
yet in this instance, the pathway of preterm labor is the primary
pathologic event. The Brighton Working Group on Pathways of
Table 1
Ultrasound features of morbidly adherent placentation [47].
Greyscale Loss of the retroplacental sonolucent zone
Irregular retroplacental sonolucent zone
Thinning or disruption of the hyperechoic serosa–bladder
interface
Presence of focal exophytic masses invading the urinary
bladder
Abnormal placental lacunae
Color doppler Diffuse or focal lacunar flow
Vascular lakes with turbulent flow (peak systolic velocity
over 15 cm/s)
Hypervascularity of serosa–bladder interface
Markedly dilated vessels over peripheral subplacental
zone
3D Power Numerous coherent vessels involving the whole uterine
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detail [3].
1.5. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper, the case definition is
accompanied by guidelines that are structured according to the
steps of conducting a clinical trial, i.e. data collection, analysis
and presentation. Case definitions and guidelines are not intended
to guide or establish criteria for management of ill infants, chil-
dren, or adults. Both were developed to improve data
comparability.
1.6. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
2. Case definition of antenatal bleeding2
2.1. For all levels of diagnostic certainty
Antenatal bleeding is a clinical syndrome characterized by
bleeding in the second or third trimester of pregnancy. Pathologic
etiologies attributable to the pregnant state include placenta pre-
via, morbidly adherent placenta, vasa previa, placental abruption,
cesarean scar pregnancy, intra-abdominal pregnancy, and uterine
rupture.
For both levels of diagnostic certainty for each etiology of ante-
natal bleeding:
 The patient is determined to be in the second or third trimester
of pregnancy (refer to Brighton Working Group document to
establish dating in pregnancy [46]).
 Bleeding is either documented vaginally or suspected to be
occurring intrauterine, intraperitoneally, or (rarely) retroperi-
toneally, based on clinical signs and symptoms.
 In the case of ultrasound-based diagnosis, transvaginal ultra-
sound is more specific than transabdominal ultrasound, and
transvaginal ultrasound is recommended where available.
For each definition, the diagnostic levels reflect diagnostic cer-
tainty and must not be misunderstood as reflecting different
grades of clinical severity. Moreover, defining levels of clinical
severity of antenatal bleeding is beyond the scope of this
document.
2.1.1. Placenta previa
Level 1 – Second or third trimester ultrasound (and/or MRI)
evidence of placental tissue overlying or abutting the
internal cervical os.
Level 2 – Painless vaginal bleeding in the second or third
trimester,
AND a high presenting part or abnormal fetal lie,
AND one of the following:
EITHER a pelvic exam with fullness palpable in the
fornices (avoiding digital cervical exam) OR a speculum
exam with tissue visible through an open cervical os2 The case definition should be applied when there is no clear alternative diagnosis
for the reported event to account for the combination of symptoms.2.1.2. Morbidly adherent placentationLevel 1 – There are two definitions of equal specificity.
Second- or third-trimester ultrasound or MRI evidence of
placenta previa,
AND one of the following ultrasound features noted in
Table 1,
AND one of the risk factors as noted in Table 2.
OR
Morbidly adherent placentation found on histology in a
hysterectomy or partial wedge resection specimen.
Level 2 – There are two definitions of equal specificity.
Ultrasound evidence of placenta previa,
AND hypervascularity at the site of the uteroplacental
interface, diagnosed at laparotomy.
OR
Difficulty with placental separation after delivery of the
infant, at either a vaginal or cesarean delivery with
resultant hemorrhage due to partial separation.2.1.3. Vasa previa
Level 1 – Second trimester ultrasound evidence of fetal
vessels (vessel with fetal heart rate identified by color flow
Doppler) running through the membranes and overlying
the internal cervical os,
AND post-delivery examination of the placental specimen
with unsupported fetal vessels within the membranes.
Level 2 – Vaginal bleeding in the second or third trimester at
the time of ruptured amniotic membranes,
AND fetal heart rate changes ultimately resulting in
sinusoidal rhythm/terminal bradycardia,
AND delivery of a pale, anemic infant or recent stillbirth or
neonatal death [48],
AND post-delivery examination of the placental specimen
with unsupported fetal vessels within the membranes.doppler serosa–bladder junction (basal view)
Hypervascularity (lateral view)
Inseparable cotyledonal and intervillous circulations,
chaotic branching, detour vessels (lateral view)
Table 2
Risk factors for morbidly adherent placentation.
Prior cesarean delivery
Prior uterine surgery (including endometrial ablation or dilation and
curettage)
Cesarean scar pregnancy
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Level 1 – There are two definitions of equal specificity.
In the absence of placenta previa on ultrasound, vaginal
bleeding in the second or third trimester,
AND one of the following:
EITHER uterine irritabilitya or labor,
OR clinical signs of hypovolemic shock or coagulopathy.
OR
Placental pathology with histologic findings of a chronic
abruption.
Level 2 – There are two definitions of equal specificity.
Vaginal bleeding in the second or third trimester,
AND uterine irritability or labor, without clinical signs of
hypovolemic shock or coagulopathy,
OR
Vaginal bleeding in the second or third trimester,
AND clinical evidence of retroplacental clot or visually
evident placental infarcts at the time of delivery.
a Uterine irritability: irregular, frequent uterine activity, not coalesced into clear
contractions in a regular pattern.3 If the reporting center is different from the vaccinating center, appropriate and2.1.5. Cesarean scar pregnancy
Level 1 – There are two definitions of equal specificity.
Transvaginal ultrasound with the following characteristics:
 empty uterine cavity, AND
 empty cervical canal, without contact with the gestational
sac, AND
 presence of gestational sac, +/ fetal pole, +/ cardiac
activity, in the anterior uterine segment adjacent to the
cesarean scar, AND
 absence or defect in myometrium between bladder and
gestational sac, AND
 gestational sac well perfused on Doppler ultrasound (to
differentiate from an expulsing, avascular gestational sac).
OR
Hysterectomy specimen with evidence of pregnancy
implanted into the cesarean scar.
There is no Level 2 definition for this condition.
2.1.6. Intra-abdominal pregnancy
Level 1 – At laparotomy, a fetus found within the abdominal
cavity, without evidence of uterine rupture, and with
placentation not within the uterine cavity.
There is no Level 2 definition for this condition.2.1.7. Uterine ruptureLevel 1 – Complete uterine disruption at the time of
laparotomy in the context of vaginal or intra-abdominal
bleeding.
There is no Level 2 definition for this condition.3. Guidelines for data collection, analysis and presentation of
antenatal bleeding
It was the consensus of the Brighton Collaboration Antenatal
Bleeding Working Group to recommend the following guidelines
to enable meaningful and standardized collection, analysis, and
presentation of information about antenatal bleeding. However,
implementation of all guidelines might not be possible in all set-
tings. The availability of information may vary depending upon
resources, geographical region, and whether the source of informa-
tion is a prospective clinical trial, post-marketing surveillance or
epidemiological study, or an individual report of antenatal bleed-
ing. Also, as explained in more detail in the overview paper in this
volume, these are intended as guidelines and are not to be consid-
ered a mandatory requirement for data collection, analysis, or
presentation.3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of available data following immunization to allow for compa-
rability of data, and are recommended as an addition to data
collected for the specific study question and setting. They are not
intended to guide the primary reporting of antenatal bleeding for
a surveillance system or study monitor. Investigators developing
a data collection tool based on these data collection guidelines also
need to refer to the criteria in the case definition, which are not
repeated in these guidelines.
Guidelines numbers below have been developed to address
data elements for the collection of adverse event information
as specified in general drug safety guidelines by the International
Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use [49], and the
form for reporting of drug adverse events by the Council for
International Organizations of Medical Sciences [50]. These data
elements include an identifiable reporter and patient, one or
more prior immunizations, and a detailed description of the
adverse event of antenatal bleeding. Additional guidelines have
been developed as direction for the collection of additional infor-
mation to allow for a more comprehensive understanding of
antenatal bleeding [4,43].3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting3 and/or
diagnosing the antenatal bleeding as specified by country-
specific data protection law.timely communication of the adverse event should occur.
4 The date and/or time of onset is defined as the time post immunization, when the
first sign or symptom indicative for antenatal bleeding occurred. This may only be
possible to determine in retrospect.
5 The date and/or time of first observation of the first sign or symptom indicative
for antenatal bleeding can be used if date/time of onset is not known.
6 The date of diagnosis of an episode is the day post immunization when the event
met the case definition at any level.
7 The end of an episode is defined as the time the event no longer meets the case
definition at the lowest level of the definition.
8 E.g. recovery to pre-immunization health status, spontaneous resolution, thera-
peutic intervention, persistence of the event, sequelae, death.
9 An AEFI is defined as serious by international standards if it meets one or more of
the following criteria: (1) it results in death, (2) is life-threatening, (3) it requires
inpatient hospitalization or results in prolongation of existing hospitalization, (4)
results in persistent or significant disability/incapacity, (5) is a congenital anomaly/
birth defect, (6) is a medically important event or reaction.
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ble for the subject, as applicable.
(4) Relation to the patient (e.g., immunizer or health care provi-
der [clinician, nurse], family member [indicate relationship],
other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants, as
appropriate, the following information should be recorded:
(5) Case/study participant identifiers (e.g. first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws).
(6) Date of birth, age, and sex.
(7) For infants: Gestational age and birth weight.
3.1.2.2. Clinical and immunization history. For all cases and/or all
study participants, as appropriate, the following information
should be recorded:
(8) Past medical history, including hospitalizations, underlying
diseases/disorders, pre-immunization signs and symptoms
including identification of indicators for, or the absence
of, a history of allergy to vaccines, vaccine components
or medications; food allergy; allergic rhinitis; eczema;
asthma.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunization includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long-term
effect. (e.g. immunoglobulins, blood transfusion and
immunosuppressants).
(10) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI)), in particular
occurrence of antenatal bleeding after a previous
immunization.
3.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(11) Date and time of immunization(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc.) and number of dose
if part of a series of immunizations against the same
disease).
(13) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically document:
(17) Clinical description of signs and symptoms of antenatal
bleeding, and if there was medical confirmation of the event
(i.e. patient seen by physician).(18) Date/time of onset,4 first observation5 and diagnosis,6 end of
episode7 and final outcome.8
(19) Concurrent signs, symptoms, and diseases.
(20) Measurement/testing. Values and units of routinely measured parameters (e.g.
temperature, blood pressure) – in particular those indi-
cating the severity of the event;
 Method of measurement (e.g. type of thermometer, oral
or other route, duration of measurement, etc.);
 Results of laboratory examinations, surgical and/or
pathological findings and diagnoses if present.(21) Treatment given for antenatal bleeding, including blood
transfusion and timing of delivery.
(22) Outcome8 at last observation.
(23) Objective clinical evidence supporting classification of the
event as ‘‘serious”.9
(24) Exposures other than the immunization 24 h before and
after immunization (e.g. food, environmental) considered
potentially relevant to the reported event.
3.1.5. Miscellaneous/ general
(25) The duration of surveillance for antenatal bleeding should be
predefined based on specific gestational age at the time of
the bleeding event and
 Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
 Biologic characteristics of the vaccine-targeted disease;
 Biologic characteristics of antenatal bleeding including
patterns identified in previous trials (e.g. early-phase tri-
als); and
 Biologic characteristics of the vaccinee (e.g. nutrition,
underlying disease like immunodepressing illness).(26) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event.
(27) Methods of data collection should be consistent within and
between study groups, if applicable.
(28) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1–24.
(29) Investigators of patients with antenatal bleeding should pro-
vide guidance to reporters to optimize the quality and com-
pleteness of information provided.
(30) Reports of antenatal bleeding should be collected through-
out the study period regardless of the time elapsed between
immunization and the adverse event. If this is not feasible
due to the study design, the study periods during which
safety data are being collected should be clearly defined.
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The following guidelines represent a desirable standard for
analysis of data on antenatal bleeding to allow for comparability
of data, and are recommended as an addition to data analyzed
for the specific study question and setting.
(31) Reported events should be classified in one of the following
five categories including the two levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 5 categories10
Event meets case definition
(1) Level 1: Criteria as specified in the Antenatal Bleeding case
definitions.
(2) Level 2: Criteria as specified in the Antenatal Bleeding case
definitions.
Event does not meet case definition
Additional categories for analysis
(3) Reported antenatal bleeding with insufficient evidence to
meet the case definition.11
(4) Not a case of antenatal bleeding.12(32) The interval between immunization and reported antena-
tal bleeding (separated out by etiology) could be defined
as the date/time of immunization to the date/time of
onset4 of the first symptoms and/or signs consistent
with the definition. If few cases are reported, the concrete
time course could be analyzed for each; for a large num-
ber of cases, data can be analyzed in the following
increments:
Subjects with Antenatal Bleeding (specify which etiology) by
Interval to Presentation1
re
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in
1
fin
shInterval0 To determine the appropriate category, the user should first establ
ported event meets the criteria for the lowest applicable level
rtainty, e.g. Level three. If the lowest applicable level of diagnostic c
finition is met, and there is evidence that the criteria of the next h
agnostic certainty are met, the event should be classified in the next
proach should be continued until the highest level of diagnostic c
ven event could be determined. Major criteria can be used t
quirement of minor criteria. If the lowest level of the case definition
ould be ruled out that any of the higher levels of diagnostic certaint
e event should be classified in additional categories four or five.
1 If the evidence available for an event is insufficient because
issing, such an event should be categorized as ‘‘Reported antenatal
sufficient evidence to meet the case definition”.
2 An event does not meet the case definition if investigation reve
ding of a necessary criterion (necessary condition) for diagnosis.
ould be rejected and classified as ‘‘Not a case of antenatal bleeding”Number<24 h after immunization
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TOTALish, whether a
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Such an event
.These intervals were arbitrarily chosen, as there is no bio-
logic plausibility between vaccination and antenatal bleed-
ing, as we have previously explained. We caution that all
episodes of bleeding that occur temporally after vaccination
may not be causally linked. For example, pre-existing condi-
tions in pregnancy (i.e., history of abdominal trauma, abnor-
mal placentation, abnormal pregnancy implantation) may
predispose a patient to an event of antenatal bleeding, with
the administration of a vaccination temporally along the
pathophysiologic process to bleeding without any relation.
In addition, we recommend recording both the gestational
age at the time of immunization, and the gestational age at
the time of the bleeding event. Please refer to the Brighton
Collaboration document on establishing gestational age.
(33) The duration of a possible antenatal bleeding event could be
analyzed as the interval between the date/time of onset3 of
the first symptoms and/or signs consistent with the defini-
tion and the end of episode7 and/or final outcome.8 What-
ever start and ending are used, they should be used
consistently within and across study groups.(34) If more than one measurement of a particular criterion is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.(35) The distribution of data (as numerator and denominator
data) could be analyzed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases is
presented, the respective values or time course can be pre-
sented individually.(36) Data on antenatal bleeding obtained from subjects receiving
a vaccine should be compared with those obtained from an
appropriately selected and documented control group(s) to
assess background rates of hypersensitivity in non-exposed
populations, and should be analyzed by study arm and dose
where possible, e.g. in prospective clinical trials.3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on antenatal bleeding that occurs in
a pregnancy in which immunizations are also administered to
allow for comparability of data, and are recommended as an addi-
tion to data presented for the specific study question and setting.
Additionally, it is recommended to refer to existing general guide-
lines for the presentation and publication of randomized controlled
trials, systematic reviews, and meta-analyzes of observational
studies in epidemiology (e.g. statements of Consolidated Standards
of Reporting Trials (CONSORT), of Improving the quality of reports
of meta-analyzes of randomized controlled trials (QUORUM), and
of meta-analysis Of Observational Studies in Epidemiology
(MOOSE), respectively).
(37) All reported events of antenatal bleeding should be presented
according to the categories listed in guideline 31 and 32.(38) Data on possible antenatal bleeding events should be pre-
sented in accordance with data collection guidelines 1–24
(verify numbers) and data analysis guidelines 31–36 (verify
numbers).(39) Terms to describe antenatal bleeding such as ‘‘low-grade”,
‘‘mild”, ‘‘moderate”, ‘‘high”, ‘‘severe” or ‘‘significant” are
highly subjective, prone to wide interpretation, and should
be avoided, unless clearly defined.
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(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denom-
inator data are usually not readily available, attempts should
be made to identify approximate denominators. The source
of the denominator data should be reported and calculations
of estimates be described (e.g. manufacturer data like total
doses distributed, reporting through Ministry of Health, cov-
erage/population based data, etc.).(41) The incidence of cases in the study population should be
presented and clearly identified as such in the text.(42) If the distribution of data is skewed, median and range are
usually the more appropriate statistical descriptors than a
mean. However, the mean and standard deviation should
also be provided.(43) Any publication of data on antenatal bleeding should include
a detailed description of the methods used for data collec-
tion and analysis as possible. It is essential to specify:13 Use
respect
ration.o The study design.
 The method, frequency and duration of monitoring for
antenatal bleeding.
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation.
 The type of surveillance (e.g. passive or active
surveillance).
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation).
 The search strategy in surveillance databases.
 Comparison group(s), if used for analysis.
 The instrument of data collection (e.g. - questionnaire,
diary card, report form).
 Whether the day of immunization was considered ‘‘day
one” or ‘‘day zero” in the analysis.
 Whether the date of onset4 and/or the date of first obser-
vation5 and/or the date of diagnosis6 was used for
analysis.
 Use of this case definition for antenatal bleeding, in the
abstract or methods section of a publication.13Disclaimer
The findings, opinions and assertions contained in this consen-
sus document are those of the individual scientific professional
members of the working group. They do not necessarily represent
the official positions of each participant’s organization.Acknowledgements
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